Type 1 Diabetes Cell Therapy: How Close Are We to a Functional Cure?

Introduction: For the First Time, Treatment Is About More Than Controlling Blood Sugar

For more than a century, the treatment of Type 1 Diabetes (T1D) has been relatively straightforward.

If the body cannot produce insulin, we replace insulin.

This approach has saved millions of lives since the discovery of insulin in 1921.

However, if we look deeper, one important fact becomes apparent:

We have never truly addressed the underlying disease.

The problem is not simply a lack of insulin. The real issue is that the immune system continues to destroy insulin-producing beta cells within the pancreas.

As a result, most diabetes therapies over the past hundred years have focused on compensating for lost pancreatic function rather than restoring it.

Whether it is insulin injections, insulin pumps, or modern artificial pancreas systems, the goal has largely been the same: helping the body perform a task that a healthy pancreas would normally do automatically.

Today, however, the field is beginning to shift.

The FDA has approved the first cellular therapy for Type 1 Diabetes. Stem cell-derived islet therapies are producing remarkable clinical results. Advances in immune modulation and cell encapsulation technologies are creating new possibilities that were difficult to imagine only a decade ago.

For the first time, scientists are seriously asking a different question:

Can we restore pancreatic function instead of simply managing blood glucose?

What Happens in Type 1 Diabetes?

The pancreas serves as the body’s natural blood glucose control center.

Within the pancreas are clusters of cells called the Islets of Langerhans, which contain several specialized cell types.

Two of the most important are:

Beta Cells

Beta cells produce insulin.

When blood glucose rises after a meal, beta cells sense the increase and release insulin to lower blood sugar levels.

Alpha Cells

Alpha cells produce glucagon.

When blood glucose drops too low, glucagon signals the liver to release stored glucose into circulation.

Together, these cell populations maintain a tightly regulated balance that keeps blood glucose within a healthy range.

In Type 1 Diabetes, however, the immune system mistakenly attacks and destroys beta cells.

Over time, the body loses its ability to produce sufficient insulin, leading to chronic hyperglycemia and potentially severe complications including:

• Cardiovascular disease

• Kidney failure

• Neuropathy

• Vision loss

Why Is Daily Life Still So Challenging for Patients?

If you have ever worked with or known someone living with Type 1 Diabetes, you quickly realize how much effort goes into managing the disease.

Every meal requires carbohydrate calculations.

Exercise requires adjustments in insulin dosing.

Illness, stress, sleep quality, and even unexpected daily activities can affect blood glucose levels.

Modern technologies such as continuous glucose monitoring (CGM) systems and insulin pumps have dramatically improved quality of life, but they still do not restore the body’s natural glucose regulation mechanisms.

This is why researchers continue searching for a more fundamental solution.

Lantidra: The First FDA-Approved Cell Therapy for Type 1 Diabetes

In 2023, the U.S. Food and Drug Administration approved Lantidra (donislecel), marking a historic milestone in diabetes treatment.

Lantidra is the first FDA-approved cellular therapy for Type 1 Diabetes.

The concept is relatively simple:

Islet cells are isolated from deceased organ donors and transplanted into patients.

In some recipients, these transplanted cells can restore insulin production and significantly reduce the need for external insulin administration.

For patients suffering from severe hypoglycemia unawareness, this can be life-changing.

However, Lantidra also highlights two major limitations that have challenged islet transplantation for decades:

1. Donor organs are scarce.

2. Recipients require long-term immunosuppressive therapy.

As a result, donor-derived islet transplantation remains difficult to scale to the broader T1D population.

Vertex VX-880: Why the Biotech Industry Is Paying Attention

While Lantidra represents an important milestone, the therapy generating the most excitement across the biotechnology industry is Vertex’s VX-880.

The idea addresses one of the biggest challenges in islet transplantation:

What if we could manufacture insulin-producing cells instead of relying on organ donors?

VX-880 uses pluripotent stem cells that are differentiated into functional islet cells and transplanted into patients.

Early clinical data have demonstrated encouraging outcomes.

Several patients have regained measurable insulin secretion.

Many have significantly reduced their insulin requirements.

Some have even achieved periods of insulin independence.

The significance of these findings goes beyond clinical performance.

For the first time, stem cell-derived islet therapies may offer a scalable source of replacement cells, potentially transforming how we think about diabetes treatment.

This has led many researchers and clinicians to discuss a concept that was once considered unrealistic:

Functional cure.

While significant hurdles remain, the possibility of restoring endogenous insulin production is no longer purely theoretical.

The Biggest Challenge Is Not Cell Production

Many people assume that generating enough beta cells is the primary challenge.

In reality, producing the cells may be only half the battle.

The autoimmune process that caused Type 1 Diabetes still exists.

Newly transplanted cells can be attacked and destroyed by the same immune mechanisms that eliminated the patient’s original beta cells.

This raises a critical question:

How do we protect transplanted cells from immune rejection?

Cell Encapsulation: Giving Cells a Protective Shield

This question has driven the development of cell encapsulation technologies, an area I became deeply interested in during my time at Cornell University.

The concept is elegant.

Encapsulate therapeutic cells within a semi-permeable biomaterial barrier.

The barrier allows:

• Oxygen to enter

• Nutrients to enter

• Glucose to diffuse inward

• Insulin to diffuse outward

At the same time, it blocks:

• Immune cells

• Antibodies

• Inflammatory mediators

In theory, encapsulation enables transplanted cells to survive and function without direct exposure to immune attack.

One notable example is the Nanofiber-Enabled Encapsulation Device (NEEDs) developed by Professor Minglin Ma’s laboratory at Cornell University.

By integrating hydrogel materials with reinforcing nanofibers, the system improves mechanical stability, long-term durability, and retrievability.

Although significant engineering challenges remain, cell encapsulation continues to be one of the most promising strategies for achieving durable cell therapy in Type 1 Diabetes.

Will Artificial Pancreas Systems Replace Cell Therapy?

Cell therapy is not the only path forward.

Artificial pancreas systems have made tremendous progress over the past decade.

Examples include:

• Omnipod 5

• Medtronic MiniMed 780G

• Tandem Control-IQ

These systems combine:

• Continuous glucose monitoring

• Insulin pumps

• Automated control algorithms

to create a closed-loop glucose management system.

For many patients, artificial pancreas technology may represent the most practical near-term solution.

However, unlike cell therapy, these systems still rely on external devices and ongoing maintenance.

The ultimate goal of cell therapy is different.

Rather than replacing pancreatic function with technology, the goal is to restore the body’s natural ability to regulate blood glucose.

For this reason, artificial pancreas systems and cell therapies are likely complementary rather than competing approaches.

LuTra Studio Perspective: Are We Finally Approaching a Cure?

Looking back at the past two decades of innovation, I believe the most important shift is not a single technological breakthrough.

It is a change in how we think about the disease itself.

For many years, the primary question was:

How can we deliver insulin more effectively?

Today, the question has evolved into:

How can we rebuild pancreatic function?

How can we protect transplanted cells?

How can we make these therapies scalable and accessible?

From stem cell engineering and immune modulation to biomaterials and translational medicine, multiple disciplines are converging toward a common goal.

This convergence is one reason why Type 1 Diabetes has become one of the most exciting applications for regenerative medicine and cell therapy.

We may not be able to say that Type 1 Diabetes has been cured.

But compared with ten years ago, we are undeniably closer than ever before.

References

• Shapiro AMJ et al. Islet transplantation in seven patients with Type 1 Diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. New England Journal of Medicine. 2000.

• An D et al. Developing robust hydrogel-based nanofiber-enabled encapsulation devices for cell therapies. Biomaterials. 2015.

• An D et al. Designing a retrievable and scalable cell encapsulation device for potential treatment of Type 1 Diabetes.PNAS. 2018.

• Wang Z et al. Dual self-regulated delivery of insulin and glucagon by a hybrid patch. PNAS. 2020.

• FDA. FDA Approves First Cellular Therapy to Treat Patients with Type 1 Diabetes. 2023.

• Vertex Pharmaceuticals. VX-880 Clinical Program Updates. 2024–2026.

• American Diabetes Association. Standards of Care in Diabetes. 2026.